{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:03:14Z","timestamp":1791932594966,"version":"4.3.4"},"reference-count":28,"publisher":"Informa UK Limited","issue":"12","funder":[{"name":"Fujian Provincial Department of Science & Technology of the People\u2019s Republic of China","award":["2017Y0035"],"award-info":[{"award-number":["2017Y0035"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["71804025"],"award-info":[{"award-number":["71804025"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia & Lymphoma"],"published-print":{"date-parts":[[2019,10,15]]},"DOI":"10.1080\/10428194.2019.1620947","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T10:56:30Z","timestamp":1559645790000},"page":"2951-2959","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Cost-effectiveness analysis on binary\/triple therapy on the basis of ixazomib or bortezomib for refractory or relapsed multiple myeloma"],"prefix":"10.1080","volume":"60","author":[{"given":"Hongfu","family":"Cai","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longfeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fujian Provincial Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maobai","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,6,4]]},"reference":[{"key":"CIT0001","unstructured":"International Agency for Research on Cancer. GLOBOCAN 2018: estimated cancer incidence and mortality and prevalence worldwide in 2018; [cited 2019 Feb 4]. Available from: http:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/160-china-fact-sheets.pdf"},{"key":"CIT0002","first-page":"866","volume":"56","author":"Chinese Hematology Association, Chinese Society of Hematology, Chinese Myeloma Committee-Chinese Hematology Association","year":"2017","journal-title":"Chin J Intern Med"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2011.0098"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.056"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0501-4"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"CIT0007","unstructured":"China National Medical Security Bureau. Notice on the inclusion of 17 kinds of anticancer drugs in the national basic medical insurance, work injury insurance and maternity insurance drugs list. Available from: http:\/\/www.gov.cn\/xinwen\/2018-10\/10\/content_5328891.htm"},{"key":"CIT0008","unstructured":"Ministry of Human Resources and Social Security. Notice on the inclusion of 36 drugs in the category B of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List. Available from: http:\/\/www.gov.cn\/xinwen\/2018-10\/10\/content_5328891.htm"},{"key":"CIT0009","unstructured":"List of Chinese administrative divisions by GDP per capita. Available from: http:\/\/en.wikipedia.org\/wiki\/List_of_Chinese_administrative_divisions_by_GDP_per_capita"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17029"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.12.007"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00617.x"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S166640"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4918"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2015.1122259"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2016-0017"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.1.29"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.136390"},{"key":"CIT0021","volume-title":"Methods for the economic evaluation of health care programmes","author":"Drummond M","year":"2015"},{"key":"CIT0022","volume-title":"Cost effectiveness thresholds","author":"World Health Organization","year":"2011"},{"key":"CIT0023","volume-title":"2015 China guidelines for pharmacoeconomic evaluations and manual","author":"Liu G","year":"2015"},{"key":"CIT0024","unstructured":"National Bureau of Statistics. Statistical Communiqu\u00e9 of the People's Republic of China on 2017 National Economic and Social Development. Available from: http:\/\/www.stats.gov.cn\/tjsj\/zxfb\/201802\/t20180228_1585631.html"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.05.012"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2017.1391088"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1194278"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.08.010"}],"container-title":["Leukemia & Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2019.1620947","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T14:37:47Z","timestamp":1602686267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2019.1620947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,4]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,10,15]]}},"alternative-id":["10.1080\/10428194.2019.1620947"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2019.1620947","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}